ПАРАТИРЕОИДНЫЙ ГОРМОН-РОДСТВ ЕННЫЙ БЕЛОК И РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

В обзоре приведена констелляция существующих фактов и аргументов о паратиреоидном гормон-родственном белке и его участии в патофизиологических и патобиохимических механизмах, связанных с онкотрансформацией ткани предстательной железы. Паратиреоидный гормон-родственный белок является мультипотентной молекулой, из которой в результате протеолитического процессинга образуются более мелкие биологически активные пептиды, участвующие в регуляции выживания, пролиферации и дифференциации клеток, в различных нормальных и патологически измененных тканях. Паратиреоидный гормон-родственный белок продуцируется клетками рака простаты и многих других опухолей. Представлены данные литературы о структуре, биохимических характеристиках и многоплановой биологической активности этого белка в организме. Основной раздел обзора посвящен информации об участии паратгормон-родственного белка в развитии рака предстательной железы, его метастазировании, влиянии на апоптоз клеток опухоли и его роли в формировании гормонрезистентности. Особое внимание уделено сведениям о биохимической основе механизмов, лежащих в основе различных эффектов, связанных с паратгормон-родственным белком при раке простаты. Представлена информация об участии паратгормон-родственного белка в модулировании фенотипических проявлений онкотрансформации ткани простаты, а также в формировании локальных и организменных реакций в ответ на лечение рака предстательной железы. Основное внимание было уделено влиянию паратгормон-родственного белка на эффекты, которые являются ключевыми в развитии рака в естественных условиях. Заключительные замечания отражают данные литературы о существующих и потенциальных возможностях использования современных представлений о паратгормон-родственном белке в клинической практике при раке предстательной железы в диагностических целях, а также в качестве мишени для противораковой терапии.

1. Курзанов А.Н., Быков И.М., Ледванов М.Ю. Паратиреоидный гормон-родственный белок – современные представления о структуре, биохимиче-ских характеристиках и физиологической роли в организме // Современные проблемы науки и образования. – 2016. – № 6.; URL: https://www.science-education.ru/ru/article/view?id=25543.

2. Alokail M.S. Molecular signalling of PTHrP in tumor. In Novel Aspects of PTHrP Physiopathology; Luparello C. Ed.; Nova Science Publishers: New York, NY, USA, 2007; pp. 191–233.

3. Ardura J.A., Rayego-Mateos S., Ramila D.et al. Parathyroid hormone-related protein promotes epithelial-mesenchymal transition // J Am Soc Nephrol 2010;21: 237–248.).

4. Arima Y., Matsueda S., Yano H. et al. Parathyroid hormone– related protein as a common target molecule in specific immunotherapy for a wide variety of tu–mor types // Int. J. Oncol. 2005;27:981–988.

5. Asadi F., Faraj M., Sharifi R. et al. Enhanced expression of parathyroid hormone–related protein in prostate cancer as compared with benign prostatic hy–perplasia // Human Pathology. 1996. 12(27): 1319–1323.

6. Asadi F., Swanson B., Zariffard R., Kukreja S. Increased Coexpression of Interleukin–6 and Parathyroid Hormone–related Peptide:A Potential Therapeutic Target and/or a Prognostic Marker for Prostate // Cancer. LOI for Portes IOM.July 2014.

7. Asadi F., Kukreja S. PTHrP expression in prostate cancer // Review: Crit. Rev.Euk.Gene Exp. 2005. 15(1): 28–42.

8. Asadi F.K.; Kukreja S.C.; Boyer, B. et al. E1A oncogene expression inhib–its PTHrP P3 promoter activity and sensitizes human prostate cancer cells to TNF–induced apoptosis // Int. Urol. Nephrol. 2010, 42, 971–978.

9. Baud'huin M., Duplomb L., RuizVelasco C. et al. Key roles of the OPG–RANK–RANKL system in bone oncology // Expert Rev Anticancer Ther 2007.–7. (2): 221–32.

10. Bhatia V., Mula R.V., Falzon M. Parathyroid hormone–related protein regulates integrin α6 and β4 levels via transcriptional and post–translational path–ways // Exp Cell Res. 2013 Jun 10; 319(10):1419–30.

11. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine–paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate.// Prostate 1991; 19: 91–8.

12. Boras–Granic K., Wysolmerski J.J. PTHrP and breast cancer: more than hypercalcemia and bone metastases // Breast Cancer Research2012 .–14:307.

13. Bryden A.A., Hoyland J.A., Freemont A.J. et al. (2002) Parathyroid hor–mone related peptide and receptor expression in paired primary prostate cancer and bone metastases // British journal of cancer 2002.–86: 322–325.

14. Bryden A.A, Islam S., Freemont A.J. et al. Parathyroid hormone–related peptide: expression in prostate cancer bone metastases // Prostate Cancer Prostatic Dis. 2002;5(1):59–62.

15. Burtis W.J., Wu T., Bunch C. et al. Identification of a novel 17, 000–dalton parathyroid hor–mone–like adenylatecyclase– stimulating protein from a tumor as–sociated with humoral hyper– calcemia of malignancy. J Biol Chem.1987. – 262:7151–7156.

16. Chen C.D., Welsbie D.S., Tran C. et al. Molecular determinants of resis–tance to antiandrogen therapy. Nat Med 2004; 10: 33–9.

17. Chiarugi, P., & Giannoni, E. Anoikis: a necessary death program for an–chorage– dependent cells // Biochemical pharmacology. 2008.– 76(11), 1352—1364.

18. Clarke N, W., Hart C.A., Brown M.D. Molecular mechanisms of metastasis in prostate cancer. // Asian Journal of Andrology. – 2009; 11: 57–67.

19. Cohen P., Peehl D.M., Graves H.C., Rosenfeld R.G. Biological effects of prostate specific antigen as an insulin–like growth factor binding protein–3 protease // J Endocrinol 1994; 142: 407–15.

20. Cramer S. et al. Parathyroid hormone–related protein (PTHrP) is an epi–dermal growth factor–regulated secretory product of human prostatic epithelial cells // Prostate 1996; 29: 20–29.

21. Cui Y., Sun Y., Hu S.et al. Neuroendocrine prostate cancer (NEPCa) in–creased the neighboring PCachemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.// Oncogene. 2016 Jul 04 [Epub ahead of print]

22. Da Silva J., Gioeli D., Weber M.J., Parsons S.J. The neuroendocrine–derived peptide parathyroid hormone–related protein promotes prostate cancer cell growth by stabilizing the androgen receptor // Cancer Res. 2009 September 15; 69 (18): 7402–7411.

23. Da Silva J.O., Amorino G.P., Casarez E.V. et al. Neuroendocrine–derived peptides promote prostate cancer cell survival through activation of IGF–1R signal–ing // Prostate. 2013; 73(8):801–12

24. Deftos L.J., Barken I., Burton D.W. et al. Direct evidence that PTHrP ex–pression promotes prostate cancer progression in bone // Biochem Biophys Res Commun 2005; 327: 468–472.

25. Dougherty K. M., Blomme E.A., Koh A.J. et al. Parathyroid hormone–related protein as a growth regulator of prostate carcinoma // Cancer Res 1999 Dec;59(23): 6015–22

26. Frieling J.S., Shay G., Lynch C.C. MMP processing of bone metastatic prostate cancer– derived PTHrP yields novel osteogenic peptides. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia (PA): AACR; Cancer Res 2015;75 (15 Suppl): Abstract nr 2386.

27. Frisch S.M., Screaton R.A. Anoikis mechanisms // Current Opinion in Cell Biology 2001;13 (5): 555–62.

28. Gagiannis S., Muller M., Uhlemann S. et al. Parathyroid hormone–related protein confers chemoresistance by blocking apoptosis signaling via death recep–tors and mitochondria // Int J Cancer. 2009 Oct 1;125(7):1551–7.

29. Gleave M. E., Hsieh J. T., von Eschenbach A. C., Chung L. W. K. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor–stromal cell interaction in prostate carcinoma growth and me–tastasis // J. Urol., 147: 1151–1159, 1992.

30. Gleave M., Hsieh J. T., Gao C. et al. Acceleration of human prostate can–cer growth in vivo by factors produced by prostate and bone fibroblasts // Cancer Res., 1991;51: 3753– 3761.

31. Guerreiro P.M, Renfro J.L, Power D.M, Canario A.V.M. The parathyroid hormone family of peptides: structure, tissue distribution, regulation, and potential functional roles in calcium and phosphate balance in fish //Am J Physiol Regul In–tegr Comp Physiol. 2007, 292 (2): R679–R696.

32. Guise T, Mundy G.R. Physiological and pathological roles of parathyroid hormone– related peptide //Curr Opinions Nephrol Hyperten 1996; 5: 307–315.

33. Guntur A.R., Doucette C.R., Rosen C.J. PTHrp comes full circle in cancer biology // BoneKEy Reports (2015) 4, Article number: 621 (2015).

34. Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy// Eur Urol 2004; 45: 586–92.

35. Hvamstad T., Jordal A., Hekmat N. et al. Neuroendocrine serum tumour markers in hormone–resistant prostate cancer // Eur Urol 2003; 44: 215–21.

36. Iddon J., Bundred N.J., Hoyland J. et al. Expression of parathyroid hor–mone–related protein and its receptor in bone metastases from prostate cancer // The Journal of pathology. 2000; 191: 170–174.

37. Iwamura M., Abrahamsson P. A., Schoen S. et al. Immunoreactive para–thyroid hormone– related protein is present in human seminal plasma and is of pros–tate origin // J. Androl., 1994;15: 410–414.

38. Iwamura M. et al. Parathyroid hormone related protein: a potential autocrine growth regulator in human prostate cancer cell lines // Urology 1994; 43: 675–679.

39. Iwamura M., di Sant'Agnese P.A., Wu G. et al. Immunohistochemical lo–calization of parathyroid hormone–related protein in human prostate cancer // Can–cer Research.–1993. – 53.– 1724–1726.

40. Iwamura M., Hellman J., Cockett A.T.et al. Alteration of the hormonal bioactivity of arathyroid hormone–related protein (PTHrP) as a result of limited proteolysis by prostate– specific antigen // Urology 1996; 48: 317–25.

41. Iwamura M., Gershagen S., Lapets O.et al. Immunohistochemical local–ization of parathyroid hormone–related protein in prostatic intraepithelial neoplasia // Hum. Pathol., 1995; 26: 797–801.

42. Iwamura M., Wu G., Abrahamsson P.A. et al. Parathyroid hormone–related protein is expressed by prostatic neuroendocrine cells. Urology. –1994.–43. –667–674.

43. Jiborn T., Bjartell A., Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment // Urology 1998; 51: 585–9.

44. Jin R., Sterling J.A., Edwards J.R. et al. Activation of NF– kappa B signal–ing promotes growth of prostate cancer cells in bone // PLoS One. 2013; 8(4):e 60983

45. Kang Y., Massagué J. Epithelial–Mesenchymal Transitions: Twist in De–velopment and Metastasis. Cell. 2004.– 118: 277–279.

46. Kremer R., Li J., Camirand A., Karaplis A.C. Parathyroid hormone related protein (PTHrP) in tumor progression // Adv Exp Med Biol. 2011;720:145–60.

47. Kronenberg H.M. PTHrP and skeletal development. Ann. N.Y. Acad. Sci. 2006 –1068: 1– 13.

48. Liao J., Li X., Koh A.J., Berry J. E. et al. Tumor expressed PTHrP facili–tates prostate cancer–induced osteoblastic lesions // Int J Cancer. 2008 Nov 15;123(10):2267–78.

49. Luparello C. Parathyroid Hormone–Related Protein (PTHrP): A Key Regulator of Life/Death Decisions by Tumor Cells with Potential Clinical Applications // Cancers 2011, 3, 396–407.

50. Mak I.W., Turcotte R.E., Ghert M. Parathyroid hormone–related protein (PTHrP) modulates adhesion, migration and invasion in bone tumor cells. Bone. 2013;55(1):198–207.

51. Mani S.A., Guo W., Liao M.J.et al. The epithelial– mesenchymal transition generates cells with properties of stem cells // Cell.2008; 133: 704–715.

52. Martin T.J. Parathyroid Hormone–Related Protein, Its Regulation of Carti–lage and Bone Development, and Role in Treating Bone Diseases // Physiological Reviews, 2016 Vol. 96 no. 3, 831–871.

53. McCauley L.K., Martin T.J. Twenty–five years of PTHrP progress: From cancer hormone to multifunctional cytokine // J Bone Miner Res. 2012, 27:1231–1239.

54. Mickle A.D., Shepherd A.J., Loo L. et al. Induction of thermal and me–chanical hypersensitivity by parathyroid hormone–related peptide through upregulation of TRPV1 function and trafficking // Pain 2015; 156: 1620–1636.

55. Morris M.J., Scher H.I. Clinical Approaches to Osseous Metastases in Prostate Cancer // The Oncologist.April, 2003, v.8, p.161–173.

56. Moseley J.M., Kubota M., Diefenbach–Jagger H. et al. Parathyroid hor–mone–related protein purified from a human lung cancer cell line // PNAS 1987.– 84 –5048–5052.

57. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic op–portunities. Nat Rev Cancer. 2002;2:584–593.

58. Noordzij M.A., van Weerden W.M., de Ridder C.M et al.Neuroendocrine differentiation in human prostatic tumor models // Am J Pathol 1996; 149: 859–71.

59. Ongkeko W.M., Burton D., Kiang A. et al. (2014) Parathyroid Hormone Related–Protein Promotes Epithelial–to–Mesenchymal Transition in Prostate Cancer // PLoS ONE 2014;9(1): e85803.

60. Otieno B.A., Krause C.E., Jones A.L. et al. Cancer Diagnostics via Ultra–sensitive Multiplexed Detection of Parathyroid Hormone–Related Peptides with a Microfluidic Immunoarray //Anal Chem. 2016 Sep 20;88(18):9269–75.

61. Park S.I. McCauley L.K. Nuclear localization of parathyroid hormonerelated peptide confers resistance to anoikis in prostate cancer cells // Endocr Relat Cancer , 2012 .–June.–19.– 243–254

62. Philbrick W.M., Wysolmersli J.J., Galbraith S. et al. Defining the roles of the parathyroid hormone–related protein in normal physiology // Physiological Re–views. 1996, 76, 127–173

63. Pinheiro P.L.C., Cardoso J.C.R., Gomes A.S. et al. Gene structure, transcripts and calciotropic effects of the PTH family of peptides in Xenopus and chicken // BMCEvol Biol.2010;10:373–379.

64. Preston D.M., Torréns J.I., Harding P.et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss // Prostate Cancer and Prostatic Diseases. 2002; 5, 304–310.

65. Rabbani S.A., Gladu J., Harakidas P. et al. Over–production of parathyroid hormonerelated peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo // Int J Cancer 1999;80: 257–264.

66. Rahim F., Hajizamani S., Mortaz E. et al . Molecular Regulation of Bone Marrow Metastasis in Prostate and Breast Cancer // Bone Marrow Research. Volume 2014 (2014), Article ID 405920, 12 rages http://dx.doi.org/10.1155/2014/405920

67. Roodman G.D. Mechanisms of bone metastasis // N Engl J Med. 2004; 350:1655–1664.

68. Rouffet J., Barlet J.P. Parathyroid hormonerelated peptide (PTHrP) and bone metabolism // Arch Physiol Biochem.–1995.– 103:3–13.

69. Ryser M.D., Qu Y., Komarova S.V. Osteoprotegerin in bone metastases: mathematical solution to the puzzle // PLoS Comput Biol. 2012; 8(10):e1002703.

70. Sakamoto S., Kyprianou N. Targeting anoikis resistancein prostate cancer metastasis // Molecular Aspects of Medicine. – 2010. –31.– 205–214.

71. Scher H.I., Sawyers C.L. Biology of progressive, castration–resistant prostate cancer: directed therapies targeting the androgen–receptor signaling axis // J Clin Oncol 2005; 23: 8253–61.

72. Schlüter K.D. PTH and PTHrP: similar structures but different functions.// Physiolo–gy.1999.Vol. 14. 6, 243–249.

73. Schneider A., Kalikin L.M., Mattos A.C. et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton // Endocrinology. 2005;146:1727–1736.

74. Seibel M.J. Clinical use of markers of bone turnover in metastatic bone disease // Nature Clinical Practice Oncology. 2005; 2, 504–517.

75. Strewler G.J., Stem P.H., Jacobs J.W. et al. Parathyroid hormonelike protein from human renal carcinoma cells structural and functional homology with parathyroid hormone // J Clin Invest.–1987.– 80:1803–1807.

76. Suva L.J., Winslow G.A., Wettenhall R.E.et al. 1987 A parathyroid hormone–related protein implicated in malignant hypercalcemia: cloning and expres–sion // Science 237 893– 896.

77. Tovar Sepulveda V.A. Differential regulation of PTHrP gene expression by 1, 25(OH)2D3 in prostate cancer cell lines. URI http://hdl.handle.net/2152.3/171

78. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nature Reviews // Cancer 2011;11, 411–425.

79. Whitfield, J.F. Parathyroid hormone–related protein (PTHrP): an ancient string of cytokines with many known and still unknown functions. In Novel As–pects of PTHrP Physiopathology; Luparello, C., Ed.; Nova Science Publishers: New York, NY, USA, 2007; pp. 1–25.

80. Wu G.1., Iwamura M., di Sant'Agnese P.A. et al. Characterization of the cell–specific expression of parathyroid hormone–related protein in normal and neoplastic prostate tissue // Urology. 1998 May;51(5A Suppl):110–120.

81. Wysolmerski J.J. Parathyroid hormone–related protein: An update // Clin.Endocrinol. Metab.2012, 97, 2947–2956.

82. Wysolmerski J.J., Stewart A.F. The physiology of parathyroid hormone–related protein: An emerging role as a developmental factor // Annu Rev Physiol.–1998.– 40:431–460.

83. Yan Z, Jin S., Wei Z. et al. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone–related protein // Biochim Biophys Acta. 2014; 1842(9):1350–63.

84. Yao A., Harada M., Matsueda S.et al. New epitope peptides derived from parathyroid hormone–related protein which have the capacity to induce prostate cancer–reactive cytotoxic T lymphocytes in HLA–A2+ prostate cancer patients // Prostate.2005;62:233–242.

85. Yilmaz M., Christofori G. (2009) EMT, the cytoskeleton, and cancer cell invasion // Cancer Metastasis Rev 28: 15–33.

86. Zafeirakis A. Collagenous and non–collagenous biochemical markers of bone metastases from prostate cancer // HIPPOKRATIA.– 2010, 14, 3: 164–169.

87. Zegarra–Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen–refractory prostate cancer cells // Cancer Res 2002; 62: 1008–13.

88. Zhang H., Yu C., Dai J., et al. Parathyroid hormone–related protein inhibits DKK1 expression through c–Junmediated inhibition of β–catenin activation of the DKK1 promoter in prostate cancer // Oncogene. 2014; 33(19):2464–77.